Sativex® as an add on therapy for spasticity in MS
Posted: Thu Oct 14, 2010 1:04 am
Almirall, S.A. announced that results from three pivotal clinical studies of Sativex® were presented in a Satellite Symposium at Europe's leading multiple sclerosis conference, the 26th annual congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), which is taking place in Gothenburg, Sweden from 13-16 October.
These Phase III studies, the main results of which were first announced some months ago, provide robust evidence of the long term efficacy of Sativex® (27 mg delta-9-tetrahydrocannabinol and 25 mg cannabidiol) in symptom improvement in patients with moderate to severe spasticity due to multiple sclerosis who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy.
These data have in recent months led to the approval of this first-in-class medication in the UK, Canada and Spain (this last country pending pricing and reimbursement conditions).1,2,3... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1814